Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shingles vaccine stays effective for years, new study confirms

NCT ID NCT02723773

Vaccine Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed over 7,500 older adults who received the shingles vaccine to see how well it prevents shingles over many years. Researchers also tested giving extra doses to some participants. The goal was to understand how long protection lasts and whether booster shots are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

7,539 people

The number who actually took part.

Started

Apr 2016

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, ability to have scheduled contacts to allow evaluation during the study). Or subjects with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, availability for follow-up contacts). * Written informed consent obtained from the subject prior to performance of any study specific procedure. * Subject who participated in ZOSTER-006 or ZOSTER-022 studies and received at least one dose of HZ/su vaccine. Additional inclusion criteria for the 1-Additional Dose Revaccination and Control groups, ONLY: * Female subjects of non-childbearing potential may be enrolled in this study. * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause. * Female subjects of childbearing potential may be enrolled in this study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. Exclusion Criteria: * Use of any investigational or non-registered product (pharmaceutical product or device) at the time of enrolment or planned use during the study period. * Previous vaccination against Varicella Zoster Virus (VZV) or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than the HZ/su vaccine administered in studies ZOSTER-006/022). * Chronic administration (defined as ≥ 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period. For corticosteroids, this will mean prednisone ≥ 20 mg/day or equivalent. A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed. * Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period. * Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, human immunodeficiency virus \[HIV\] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders). * Administration of immunoglobulins and/or any blood products within 3 months prior to Visit Month 0 of study ZOSTER-049 or planned administration during the study period. * Prolonged use (\> 14 consecutive days) of oral and/or parenteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ-related complication (topical use of these antiviral agents is allowed). * Important underlying illness that in the opinion of the investigator would be expected to interfere significantly during the study. Additional exclusion criteria for the 1-Additional Dose Revaccination and Control groups, only: * Subjects who experienced an SAE from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049 that was considered related to study vaccine by either the investigator or the sponsor. * Subjects with a new onset of a pIMD or exacerbation of a pIMD from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049. * Use of any investigational or non-registered product (pharmaceutical product or device) within 30 days preceding the first dose of study vaccine or planned use during the study period. * Administration or planned administration of any other immunizations within 30 days before the first study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines for seasonal or pandemic flu, with or without adjuvant) may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation (such as materials that may possibly contain latex-gloves, syringes, etc.). Please note, the vaccine and vials in this study do not contain latex. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential). * Previous episode/history of HZ.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster Herpes zoster vaccine

Contacts and locations

Locations

  • GSK Investigational Site

    Phoenix, Arizona, 29651, United States

  • GSK Investigational Site

    Phoenix, Arizona, 84123, United States

  • GSK Investigational Site

    Phoenix, Arizona, 85018, United States

  • GSK Investigational Site

    Phoenix, Arizona, 85020, United States

  • GSK Investigational Site

    Phoenix, Arizona, 85306, United States

  • GSK Investigational Site

    Spring Valley, California, 91978, United States

  • GSK Investigational Site

    Hallandale, Florida, 85213, United States

  • GSK Investigational Site

    Boise, Idaho, 83712, United States

  • GSK Investigational Site

    Wichita, Kansas, 67207, United States

  • GSK Investigational Site

    Columbia, Maryland, 21045, United States

  • GSK Investigational Site

    Elkridge, Maryland, 21075, United States

  • GSK Investigational Site

    Cary, North Carolina, 27518, United States

  • GSK Investigational Site

    Charlotte, North Carolina, 28209, United States

  • GSK Investigational Site

    Hickory, North Carolina, 28601, United States

  • GSK Investigational Site

    Salisbury, North Carolina, 28144, United States

  • GSK Investigational Site

    Wilmington, North Carolina, 28412, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    Cleveland, Ohio, 44122, United States

  • GSK Investigational Site

    Wadsworth, Ohio, 44281, United States

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15236, United States

  • GSK Investigational Site

    Uniontown, Pennsylvania, 15401, United States

  • GSK Investigational Site

    Mt. Pleasant, South Carolina, 29464, United States

  • GSK Investigational Site

    Bristol, Tennessee, 37620, United States

  • GSK Investigational Site

    San Antonio, Texas, 78229, United States

  • GSK Investigational Site

    Newport News, Virginia, 23606, United States

  • GSK Investigational Site

    Westmead, New South Wales, 2145, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, 2522, Australia

  • GSK Investigational Site

    Geelong, Victoria, 3220, Australia

  • GSK Investigational Site

    Belo Horizonte, 30150-320, Brazil

  • GSK Investigational Site

    Curitiba, 80069-900, Brazil

  • GSK Investigational Site

    CuritibaPR, 80240-000, Brazil

  • GSK Investigational Site

    São Paulo, 04266-010, Brazil

  • GSK Investigational Site

    São Paulo, 04312903, Brazil

  • GSK Investigational Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • GSK Investigational Site

    Victoria, British Columbia, V8V 3M9, Canada

  • GSK Investigational Site

    Halifax, Nova Scotia, B3K 6R8, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, B2N 1L2, Canada

  • GSK Investigational Site

    Toronto, Ontario, M4S 1Y2, Canada

  • GSK Investigational Site

    Toronto, Ontario, M9W 4L6, Canada

  • GSK Investigational Site

    Woodstock, Ontario, N4V 0E1, Canada

  • GSK Investigational Site

    Gatineau, Quebec, J8Y1W2, Canada

  • GSK Investigational Site

    Montreal, Quebec, J7J 2K8, Canada

  • GSK Investigational Site

    Pointe-Claire, Quebec, H9R 4S3, Canada

  • GSK Investigational Site

    Québec, Quebec, G1E 7G9, Canada

  • GSK Investigational Site

    Québec, Quebec, G1W 4R4, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, J1J 2G2, Canada

  • GSK Investigational Site

    Brno, 612 00, Czechia

  • GSK Investigational Site

    České Budějovice, 370 05, Czechia

  • GSK Investigational Site

    Hradec Králové, 500 05, Czechia

  • GSK Investigational Site

    Tallinn, 13619, Estonia

  • GSK Investigational Site

    Tartu, 50106, Estonia

  • GSK Investigational Site

    Espoo, 02230, Finland

  • GSK Investigational Site

    Helsinki, 00100, Finland

  • GSK Investigational Site

    Helsinki, 00930, Finland

  • GSK Investigational Site

    Jarvenpaa, 04400, Finland

  • GSK Investigational Site

    Kokkola, 67100, Finland

  • GSK Investigational Site

    Oulu, 90220, Finland

  • GSK Investigational Site

    Pori, 28100, Finland

  • GSK Investigational Site

    Seinäjoki, 60100, Finland

  • GSK Investigational Site

    Tampere, 33100, Finland

  • GSK Investigational Site

    Turku, 20520, Finland

  • GSK Investigational Site

    Angers, 49000, France

  • GSK Investigational Site

    Angers, 49100, France

  • GSK Investigational Site

    Château-Gontier, 53200, France

  • GSK Investigational Site

    Clermont-Ferrand, 63003, France

  • GSK Investigational Site

    Laval, 53000, France

  • GSK Investigational Site

    Montrevault, 49110, France

  • GSK Investigational Site

    Muret, 31600, France

  • GSK Investigational Site

    Mûrs-Erigné, 49610, France

  • GSK Investigational Site

    Nantes, 44300, France

  • GSK Investigational Site

    Rosiers-d'Égletons, 19300, France

  • GSK Investigational Site

    Segré, 49500, France

  • GSK Investigational Site

    Tours, 37100, France

  • GSK Investigational Site

    Berlin, 10629, Germany

  • GSK Investigational Site

    Berlin, 10787, Germany

  • GSK Investigational Site

    Berlin, 13347, Germany

  • GSK Investigational Site

    Cologne, 51069, Germany

  • GSK Investigational Site

    Dachau, 85221, Germany

  • GSK Investigational Site

    Dresden, 01097, Germany

  • GSK Investigational Site

    Essen, 45355, Germany

  • GSK Investigational Site

    Essen, 45359, Germany

  • GSK Investigational Site

    Flörsheim, 65439, Germany

  • GSK Investigational Site

    Freiberg, 09599, Germany

  • GSK Investigational Site

    Goch, 47574, Germany

  • GSK Investigational Site

    Güglingen, 74363, Germany

  • GSK Investigational Site

    Hamburg, 20251, Germany

  • GSK Investigational Site

    Hamburg, 22143, Germany

  • GSK Investigational Site

    Hamburg, 22415, Germany

  • GSK Investigational Site

    Köthen, 06366, Germany

  • GSK Investigational Site

    Künzing, 94550, Germany

  • GSK Investigational Site

    Leipzig, 04315, Germany

  • GSK Investigational Site

    Lübeck, 23554, Germany

  • GSK Investigational Site

    Magdeburg, 39112, Germany

  • GSK Investigational Site

    Mainz, 55116, Germany

  • GSK Investigational Site

    Mannheim, 68161, Germany

  • GSK Investigational Site

    München, 80339, Germany

  • GSK Investigational Site

    Rednitzhembach, 91126, Germany

  • GSK Investigational Site

    Rhaunen, 55624, Germany

  • GSK Investigational Site

    Tübingen, 72074, Germany

  • GSK Investigational Site

    Wallerfing, 94574, Germany

  • GSK Investigational Site

    Wangen, 88239, Germany

  • GSK Investigational Site

    Weinheim, 69469, Germany

  • GSK Investigational Site

    Witten, 58455, Germany

  • GSK Investigational Site

    Würzburg, 97070, Germany

  • GSK Investigational Site

    Kwun Tong Kowloon, Hong Kong

  • GSK Investigational Site

    Shatin, 000000, Hong Kong

  • GSK Investigational Site

    Chieti, 66013, Italy

  • GSK Investigational Site

    Genova, 16132, Italy

  • GSK Investigational Site

    Monza MB, 20900, Italy

  • GSK Investigational Site

    Roma, 00163, Italy

  • GSK Investigational Site

    Sassari, 07100, Italy

  • GSK Investigational Site

    Fukuoka, 810-0021, Japan

  • GSK Investigational Site

    Fukuoka, 812-0025, Japan

  • GSK Investigational Site

    Fukuoka, 813-8588, Japan

  • GSK Investigational Site

    Fukuoka, 816-0864, Japan

  • GSK Investigational Site

    Kanagawa, 224-8503, Japan

  • GSK Investigational Site

    Kanagawa, 247-8533, Japan

  • GSK Investigational Site

    Tokyo, 142-0054, Japan

  • GSK Investigational Site

    Tokyo, 142-8666, Japan

  • GSK Investigational Site

    Tokyo, 154-0024, Japan

  • GSK Investigational Site

    Durango, 34000, Mexico

  • GSK Investigational Site

    Zapopan Jalisco, 45190, Mexico

  • GSK Investigational Site

    Ansan, 425-707, South Korea

  • GSK Investigational Site

    Bucheon-si Kyunggi-do 14584, 420-767, South Korea

  • GSK Investigational Site

    Incheon, 400-711, South Korea

  • GSK Investigational Site

    Kangwon-do, 220-701, South Korea

  • GSK Investigational Site

    Seoul, 150-950, South Korea

  • GSK Investigational Site

    Seoul, 152-703, South Korea

  • GSK Investigational Site

    Alcover Tarragona, 43460, Spain

  • GSK Investigational Site

    Barcelona, 08025, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Barcelona, 08430, Spain

  • GSK Investigational Site

    Barcelona, 08540, Spain

  • GSK Investigational Site

    Barcelona, 28500, Spain

  • GSK Investigational Site

    Hostalets de Balenya Ba, 08550, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

  • GSK Investigational Site

    Peralada Girona, 17491, Spain

  • GSK Investigational Site

    Valencia, 46020, Spain

  • GSK Investigational Site

    Borås, SE-506 30, Sweden

  • GSK Investigational Site

    Eskilstuna, SE-631 88, Sweden

  • GSK Investigational Site

    Gothenburg, SE-413 45, Sweden

  • GSK Investigational Site

    Jönköping, SE-551 85, Sweden

  • GSK Investigational Site

    Karlskrona, SE-371 79, Sweden

  • GSK Investigational Site

    Linköping, SE-58758, Sweden

  • GSK Investigational Site

    Malmö, SE-211 52, Sweden

  • GSK Investigational Site

    Örebro, SE-703 62, Sweden

  • GSK Investigational Site

    Stockholm, 11446, Sweden

  • GSK Investigational Site

    Uppsala, SE-751 85, Sweden

  • GSK Investigational Site

    Vällingby, SE-194 61, Sweden

  • GSK Investigational Site

    Taichung, 40447, Taiwan

  • GSK Investigational Site

    Taipei, 10002, Taiwan

  • GSK Investigational Site

    Taipei, 112, Taiwan

  • GSK Investigational Site

    Tau-Yuan, 333, Taiwan

  • GSK Investigational Site

    Atherstone Warwickshire, CV9 1EU, United Kingdom

  • GSK Investigational Site

    Belfast, BT7 2EB, United Kingdom

  • GSK Investigational Site

    Bradford on Avon Wiltsh, BA15 1DQ, United Kingdom

  • GSK Investigational Site

    Broughshane, BT42 4JP, United Kingdom

  • GSK Investigational Site

    Chorley, PR7 7NA, United Kingdom

  • GSK Investigational Site

    Liverpool, L22 0LG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.